News

Under the terms of the agreement, Endotis has acquired exclusive rights to develop and commercialize Org 42675, Org 217609 (a neutralizable follow-up of Org 42675) and Org 224283,

ChemGenex’s metabolic disease assets currently reside within the company’s wholly-owned subsidiary Autogen Research, which is to be renamed Verva Pharmaceuticals. Pending shareholder approval at the annual general meeting,

Findings from trial of obese, but otherwise healthy, adults demonstrated that adults taking 600mg of drug twice-daily (n=11) for 28 days lost an average of 0.45 kg (1

In the SWEET (simplification with easier emtricitabine and tenofovir) study, patients who switched from Combivir to Truvada, both in combination with once-daily Sustiva (efavirenz), experienced improvements in a

As part of this action, Cathleen Davis, the company’s vice president, finance and controller and Kevin Kaster, the company’s senior vice president, corporate development will leave the company.

Pursuant to the terms of the termination agreement, King has paid Depomed termination and other fees of approximately $30 million, and Depomed will not pay King a promotion

Cardica, a provider of automated anastomosis systems for coronary artery bypass graft surgery, will not receive any proceeds from sales of shares made by the selling stockholder and

Medical device maker Insulet has granted the underwriters the right to purchase up to an additional 734,759 shares to cover over-allotments, if any. Insulet will not receive any

All of IsoTis’s outstanding $12.6 million in debt was repaid at closing. Integra, which focuses on advanced technology in orthobiologics, intends to integrate both IsoTis’s domestic network of